NCT06272942

Brief Summary

This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied. ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult. In observational studies, only observations are made without participants receiving any advice or any changes to health care. People who are admitted to ICU for serious illnesses, like ARDS, often experience new health problems during and after their ICU stays. These health problems that may include physical, mental, and/or emotional disorders, are called post-intensive care syndrome (PICS). Identifying these new health problems early can help people by timely treatments and care. In this study, researchers want to identify any health problems that arise after ICU admission in people with ARDS in the United States (US). To do this, researchers will collect information on health problems, treatments, medicines, and healthcare visits in people with ARDS, 1 year before and after an ICU admission. They will then look to see whether the health problems are in areas that have been described as the post intensive care syndrome (PICS). In addition, they will measure healthcare related costs in the one year after admission and compare it to the one year prior to admission. Researchers will also compare this information with data collected for people with pneumonia who did not require ICU admission. This will help them to identify any new health problems arising due to ICU stays. The data will come from participants' medical claims information stored in the Optum Clinformatics Data Mart database from 2016 to 2022. The claims data will only be collected for people in the US. Researchers will collect data from participants admitted to ICU for ARDS for a maximum of 1 year before and after their stay.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
640,058

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 31, 2024

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

February 15, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 22, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

April 2, 2026

Status Verified

March 1, 2026

Enrollment Period

2.2 years

First QC Date

February 15, 2024

Last Update Submit

April 1, 2026

Conditions

Outcome Measures

Primary Outcomes (6)

  • Morbidity

    Morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.

    at 1,3,6 and 12 month pre- and post- index hospital admission

  • Post ICU Syndrome-related morbidity

    PICS-related morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization. PICS stands for post intensive care unit syndrome.

    at 12 months post- index hospital admission

  • Incident morbidity

    Incident morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.

    at 1, 3, 6 and 12 months post- index hospital admission

  • Post ICU Syndrome-related incident morbidity

    PICS-related incident morbidity will be stratified by comorbidities, procedures, medications, healthcare utilization.

    at 1, 3, 6 and 12 months post- index hospital admission

  • Difference in prevalence rates pre versus post index hospitalization

    at 1, 3, 6 and 12 months post- index hospital admission

  • Average total healthcare costs based on healthcare billing data in the one year post index ICU admission

    Average total healthcare costs will be based on healthcare billing data in the one year post index ICU admission.

    at 12 months post- index hospital admission

Other Outcomes (1)

  • Exploratory, descriptive difference in ranking of PICS domain comorbidity ratios observed for ARDS (ICU admissions) versus pneumonia (non ICU admissions).

    At 1, 3, 6 and 12 months post-index admission

Study Arms (1)

Post intensive care unit (ICU) morbidity

All adult patients in Optum Claims data from January 1, 2016 until October 1, 2022.

Other: An ICU admission and a temporally related ARDS diagnosis

Interventions

This is a disease study to learn more about the morbidity after an ICU admission and a temporally related ARDS diagnosis. ARDS stands for acute respiratory distress syndrome.

Post intensive care unit (ICU) morbidity

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All adult patients in Optum Claims data with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) from January 1, 2016 until October 1, 2022.

You may qualify if:

  • continuous coverage of at least 365 days (\>= 1 year) pre-index date for the cohort
  • age \>= 18 years
  • not seen outside the healthcare system

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bayer

Whippany, New Jersey, 07981, United States

Location

MeSH Terms

Conditions

Respiratory Distress Syndromepostintensive care syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2024

First Posted

February 22, 2024

Study Start

January 31, 2024

Primary Completion

March 31, 2026

Study Completion

March 31, 2026

Last Updated

April 2, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Locations